Skip to main content

Abbvie Value Stock - Dividend - Research Selection


ISIN: US00287Y1091 , WKN: A1J84E

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

AbbVie is a global, research-based biopharmaceutical company. AbbVie develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. AbbVie also has a pipeline of promising new medicines, including more than 50 investigational programs in clinical development across such important medical specialties as immunology, virology, oncology and neurology, with additional targeted investment in cystic fibrosis and women's health.


AbbVie was incorporated in Delaware on April 10, 2012. On January 1, 2013, AbbVie became an independent company as a result of the distribution by Abbott Laboratories (Abbott) of 100% of the outstanding common stock of AbbVie to Abbott's shareholders.


On June 1, 2016, AbbVie acquired all of the outstanding equity interests in Stemcentrx, Inc. (Stemcentrx), a privately held biotechnology company. The aggregate upfront consideration paid by AbbVie in connection with the acquisition was approximately $5.8 billion. The transaction expands AbbVie’s oncology pipeline by adding the late-stage asset rovalpituzumab tesirine (Rova-T), four additional early-stage clinical compounds in solid tumor indications and a significant portfolio of pre-clinical assets. Rova-T is currently in registrational trials for small cell lung cancer and in early-stage clinical development for other solid tumors.



AbbVie operates in one business segment—pharmaceutical products. See Note 15 to the Consolidated Financial Statements and the sales information related to HUMIRA included under Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations—Results of Operations."

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


GLP-1 drugs may already be impacting aesthetics sectors, survey finds

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug

China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab. AbbVie's decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia. The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab.

20 Most Innovative Companies in America

In this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology […]

AbbVie Inc. stock outperforms competitors despite losses on the day

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

AbbVie Stock Shows Rising Relative Strength Rating

On Thursday, AbbVie stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 71. See if AbbVie stock can continue to show renewed price strength and hit that benchmark. Is AbbVie Stock A Buy?

3 Bargain Stocks to Buy in a Market That's Priced for Perfection

Stock valuations are at historically high levels. Three Motley Fool contributors identified bargain stocks to buy in a market that's priced for perfection. Here's why they picked AbbVie (NYSE: ABBV), Gilead Sciences (NASDAQ: GILD), and Pfizer (NYSE: PFE).

Only 7 Large-Cap Dividend Kings Yield Over 3%. Here's My Top Pick to Buy Now.

If you're an income investor, you may have heard tales of mighty companies that have raised their payouts no matter the economic cycle. Target (NYSE: TGT), Coca-Cola (NYSE: KO), Kimberly-Clark (NYSE: KMB), AbbVie (NYSE: ABBV), Altria (NYSE: MO), Stanley Black & Decker (NYSE: SWK), and 3M (NYSE: MMM) are the seven companies that stand alone on the throne of large-cap Dividend Kings with a yield over 3%.

10 Health Care Stocks Whale Activity In Today's Session

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

AbbVie (NYSE:ABBV) Has A Pretty Healthy Balance Sheet

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

Interesting ABBV Put And Call Options For November 3rd

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.